270 related articles for article (PubMed ID: 25846418)
1. Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries.
Laudano MA; Seklehner S; Sandhu J; Reynolds WS; Garrett KA; Milsom JW; Te AE; Kaplan SA; Chughtai B; Lee RK
J Urol; 2015 Aug; 194(2):449-53. PubMed ID: 25846418
[TBL] [Abstract][Full Text] [Related]
2. Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention.
Suskind AM; Clemens JQ; Zhang Y; Hollenbeck BK
Urology; 2015 Jul; 86(1):30-4. PubMed ID: 26026856
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
[TBL] [Abstract][Full Text] [Related]
4. Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience.
Groen LA; Hoebeke P; Loret N; Van Praet C; Van Laecke E; Ann R; Vande Walle J; Everaert K
J Urol; 2012 Oct; 188(4):1313-7. PubMed ID: 22902022
[TBL] [Abstract][Full Text] [Related]
5. Sacral neuromodulation in urological indications: the Finnish experience.
Vaarala MH; Tammela TL; Perttilä I; Luukkonen P; Hellström P
Scand J Urol Nephrol; 2011 Feb; 45(1):46-51. PubMed ID: 20961268
[TBL] [Abstract][Full Text] [Related]
6. Sacral neuromodulation in children with urinary and fecal incontinence: a multicenter, open label, randomized, crossover study.
Haddad M; Besson R; Aubert D; Ravasse P; Lemelle J; El Ghoneimi A; Moscovici J; Hameury F; Baumstarck-Barrau K; Hery G; Guys JM
J Urol; 2010 Aug; 184(2):696-701. PubMed ID: 20561645
[TBL] [Abstract][Full Text] [Related]
7. Long term safety of sacral nerve modulation in medicare beneficiaries.
Chughtai B; Sedrakyan A; Isaacs A; Lee R; Te A; Kaplan S
Neurourol Urodyn; 2015 Sep; 34(7):659-63. PubMed ID: 25066920
[TBL] [Abstract][Full Text] [Related]
8. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence.
Mellgren A; Wexner SD; Coller JA; Devroede G; Lerew DR; Madoff RD; Hull T;
Dis Colon Rectum; 2011 Sep; 54(9):1065-75. PubMed ID: 21825885
[TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
11. Single Institutional Experience with Single Stage Sacral Neuromodulation: Cost Savings and Outcomes in a Contemporary Case Series.
Lee W; Artenstein D; Tenggardjaja CF; Lee UJ; Lucioni A; Reyblat P; Kobashi KC
J Urol; 2020 Mar; 203(3):604-610. PubMed ID: 31584846
[TBL] [Abstract][Full Text] [Related]
12. Outcomes associated with Interstim therapy for medically refractory fecal incontinence.
McNevin MS; Moore M; Bax T
Am J Surg; 2014 May; 207(5):735-7; discussion 737-88. PubMed ID: 24791636
[TBL] [Abstract][Full Text] [Related]
13. Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation.
Devroede G; Giese C; Wexner SD; Mellgren A; Coller JA; Madoff RD; Hull T; Stromberg K; Iyer S;
Female Pelvic Med Reconstr Surg; 2012; 18(2):103-12. PubMed ID: 22453321
[TBL] [Abstract][Full Text] [Related]
14. Can sacral neuromodulation improve minor incontinence symptoms in doubly incontinent patients successfully treated for major incontinence symptoms?
Caremel R; Damon H; Ruffion A; Chartier-Kastler E; Gourcerol G; Michot F; Menard JF; Grise P; Leroi AM
Urology; 2012 Jan; 79(1):80-5. PubMed ID: 22099864
[TBL] [Abstract][Full Text] [Related]
15. Battery explantation after sacral neuromodulation in the Medicare population.
Cameron AP; Anger JT; Madison R; Saigal CS; Clemens JQ;
Neurourol Urodyn; 2013 Mar; 32(3):238-41. PubMed ID: 22847359
[TBL] [Abstract][Full Text] [Related]
16. Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention.
Penson DF
J Urol; 2016 Mar; 195(3):689. PubMed ID: 26887733
[No Abstract] [Full Text] [Related]
17. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study.
Myer ENB; Petrikovets A; Slocum PD; Lee TG; Carter-Brooks CM; Noor N; Carlos DM; Wu E; Van Eck K; Fashokun TB; Yurteri-Kaplan L; Chen CCG
Am J Obstet Gynecol; 2018 Jul; 219(1):78.e1-78.e9. PubMed ID: 29630890
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
19. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation.
Martinson M; MacDiarmid S; Black E
J Urol; 2013 Jan; 189(1):210-6. PubMed ID: 23174264
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of sacral neuromodulation in 23 children.
Humphreys MR; Vandersteen DR; Slezak JM; Hollatz P; Smith CA; Smith JE; Reinberg YE
J Urol; 2006 Nov; 176(5):2227-31. PubMed ID: 17070300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
